What can we learn from the edaravone development program for ALS? - Wikidata - wikimedia - TriplyDB

What can we learn from the edaravone development program for ALS?

What can we learn from the edaravone development program for ALS?

http://www.wikidata.org/entity/Q50222481

about

Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.

P2860

Q48240848-F609C875-4248-491D-BE79-D970FEBA75D9

P2860

What can we learn from the edaravone development program for ALS?

http://www.wikidata.org/entity/Q50222481

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

What can we learn from the edaravone development program for ALS?

@en

What can we learn from the edaravone development program for ALS?

@nl

type

label

What can we learn from the edaravone development program for ALS?

@en

What can we learn from the edaravone development program for ALS?

@nl

prefLabel

What can we learn from the edaravone development program for ALS?

@en

What can we learn from the edaravone development program for ALS?

@nl

P1433

Q50222481-DD8D968B-7F24-4A07-92BC-AF81906ED0F7

P1476

Q50222481-361F3630-CF08-4978-BFE2-E2A603E64147

P2093

Q50222481-4B6F5F06-88E2-4AC1-8F9C-31C0CD9107B9

P2860

Q50222481-0B14F45A-E46F-483D-BB61-7262D18F02A2

Q50222481-19F3636E-9F40-43B0-8719-D77D341109FE

Q50222481-1FE17914-8876-4CFC-BF5C-1D28880CCF65

Q50222481-229027D6-2E7C-41C3-A113-135388A8BA3B

Q50222481-31B6FCFA-1126-41B0-8922-C8A86BBC562B

Q50222481-3F4BE7BD-A112-48D6-B45E-364BDC755C05

Q50222481-4C3061E2-4480-4D4E-9F37-FF7FEE9E6191

Q50222481-4F687D02-D2B7-445F-9BAB-0234EE84D198

Q50222481-54956FEC-580C-4298-9028-447CFCC7FBA8

Q50222481-552AC308-8FCE-47AB-BF87-180363CEB421

P304

Q50222481-A4613A4E-2FE3-4F1A-AA58-7B23116BA34C

P31

Q50222481-EEC2BB53-1EAF-4052-BDFC-4E480784C001

P356

Q50222481-08ECBF7E-529E-475D-8272-9ECC2CEBE5A8

P433

Q50222481-92FF6F57-7DD9-4B1A-B524-7A4737B83EDD

P478

Q50222481-EACEA9B6-7C43-46FF-9F1D-CC4B5E0EA875

P577

Q50222481-47B802E7-DAC7-45C9-BBA5-5DF2EA76206F

P698

Q50222481-A2F57493-3333-45A8-BB72-9B64E5EB0A5E

P921

Q50222481-6D58CE40-B9DB-4005-8284-42CB207431CA

Q50222481-924DEA21-5887-4837-B56E-1D5566AB5B4B

P356

21678421.2017.1361446

P1433

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

P1476

What can we learn from the edaravone development program for ALS?

@en

P2093

Nicholas J Maragakis

http://www.w3.org/2001/XMLSchema#string

P2860

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

Treatment of acute ischemic stroke: recent progress

Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis

Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse

Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

Neuroprotective agents for clinical trials in ALS: a systematic assessment.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Lost in translation: treatment trials in the SOD1 mouse and in human ALS.

P304

98-103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21678421.2017.1361446

http://www.w3.org/2001/XMLSchema#string

P433

sup1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28872911

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis